Bellerophon Therapeutics, Inc. (BLPH) Upgraded by Zacks Investment Research to “Buy”
Zacks Investment Research upgraded shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) from a hold rating to a buy rating in a research note released on Friday. Zacks Investment Research currently has $1.25 price objective on the biotechnology company’s stock.
According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. “
A number of other brokerages also recently issued reports on BLPH. HC Wainwright reiterated a buy rating and issued a $5.00 price objective on shares of Bellerophon Therapeutics in a research report on Wednesday, September 6th. ValuEngine upgraded Bellerophon Therapeutics from a strong sell rating to a sell rating in a research report on Friday, September 8th.
Bellerophon Therapeutics (NASDAQ BLPH) traded up 1.94% during mid-day trading on Friday, reaching $1.05. The company had a trading volume of 508,102 shares. Bellerophon Therapeutics has a one year low of $0.43 and a one year high of $1.69. The company’s 50-day moving average is $1.08 and its 200-day moving average is $1.20. The stock’s market capitalization is $37.29 million.
Bellerophon Therapeutics (NASDAQ:BLPH) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.03. Equities research analysts anticipate that Bellerophon Therapeutics will post ($1.12) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Bellerophon Therapeutics, Inc. (BLPH) Upgraded by Zacks Investment Research to “Buy”” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/09/16/bellerophon-therapeutics-inc-blph-upgraded-by-zacks-investment-research-to-buy.html.
A number of institutional investors have recently bought and sold shares of BLPH. Goldman Sachs Group Inc. purchased a new position in shares of Bellerophon Therapeutics during the first quarter valued at approximately $125,000. Renaissance Technologies LLC lifted its holdings in shares of Bellerophon Therapeutics by 99.7% during the first quarter. Renaissance Technologies LLC now owns 477,400 shares of the biotechnology company’s stock valued at $711,000 after purchasing an additional 238,300 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Bellerophon Therapeutics by 52.6% during the second quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock valued at $821,000 after purchasing an additional 211,111 shares during the last quarter. Finally, Susquehanna International Group LLP purchased a new position in shares of Bellerophon Therapeutics during the second quarter valued at approximately $1,316,000. 45.85% of the stock is currently owned by institutional investors and hedge funds.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.
Receive News & Stock Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related stocks with our FREE daily email newsletter.